跳至主要内容
临床试验/EUCTR2017-004797-33-BE
EUCTR2017-004797-33-BE进行中(未招募)1 期

The efficacy of continuous ropivacaine wound infusion after cesarean delivery in pain management.

CHU Tivoli0 个研究点目标入组 68 人开始时间: 2018年4月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Inclusion criteria will be all patients undergoing cesarean delivery with
  • - a gestation of 34 weeks or more
  • - American Society of Anesthesiology (ASA) I or II
  • - = age 18 years
  • - signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 68
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Exclusion criteria will be
  • - allergies to used analgesics
  • - ASA III or higher
  • - pre- or eclampsia
  • - diabetes mellitus type I or II
  • - postpartum hemorrhage (defined as = 1 L blood loss)
  • - BMI = 35
  • - preoperative opioid consumption/abuse
  • - psychiatric disorders
  • - patient refusal to participate
  • - language barrier

研究者

发起方
CHU Tivoli

相似试验